Hyaluronic Acid Hybrid Cooperative Complexes Nearing 10 Years of Use: Update on Safety Assessment Based on Post‐Marketing Surveillance Data
Journal of Cosmetic Dermatology · 2025
DOI: 10.1111/jocd.70197 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cosmetic Dermatology, 2025. Verfasst von Giovanni Salti und 8 weiteren Autor:innen. Beteiligte Einrichtung: Medlight Institute, Florence, Italy. Hauptthemen laut MEDLINE: Hyaluronic Acid, Dermal Fillers, Cosmetic Techniques. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Hybrid cooperative complex hyaluronic acid (HCC HA) is a novel, widely used injectable developed using the patented NAHYCO Hybrid Technology for the treatment of the face and body, respectively.
Aim
To examine the safety profile of HCC HA from global post‐marketing surveillance data.
Methods
Post‐marketing adverse events (AEs) reported for HCC HA injected to the face (Profhilo, HCC‐HA PROF , IBSA Farmaceutici Italia Srl, Italy) from January 1, 2018 to October 31, 2023 and to the body (Profhilo Body, HCC‐HA PROF‐B , IBSA Farmaceutici Italia Srl, Italy) from January 1, 2020 to October 31, 2023 were analyzed. Patient exposure and the proportion of exposed patients with a safety complaint were also estimated.
Results
The total number of patients exposed to HCC‐HA PROF and HCC‐HA PROF‐B globally was projected to be 1 091 956 and 27 692, respectively. There was a total of 371 AEs recorded for HCC‐HA PROF , and 11 AEs reported for HCC‐HA PROF‐B , corresponding to 0.034% and 0.040% of the patients, respectively. The most common AEs were edema, erythema, and discomfort, which are consistent with the manner and location of administration, and the AEs are frequently reported following treatment. The proportion of exposed patients with a safety complaint was low, with 0.026%–0.050% and 0%–0.013% of patients exposed to HCC‐HA PROF or HCC‐HA PROF‐B experiencing a safety complaint, respectively.
Conclusions
Post‐marketing surveillance indicated favorable safety profiles for HCC‐HA PROF and HCC‐HA PROF‐ , with the most common AEs expected and/or related to the method or site of administration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medlight Institute, Florence, Italy.
- Private Practice, Milan and Pavia, Italy.
- Private Practice, Israel.
- Private Practice, Milan, Italy.
- Agorà Clinical Educational Centre, Milan, Italy.
- IBSA Institut Biochimique SA, Lugano, Switzerland.
ORCID-Profile: Clara Cigni
Zitieren
APA
Salti, G., Tateo, A., Cassuto, D., Arrigoni, F., Godina, C., Mazzola, F., Cigni, C., Grimolizzi, F., & Bellia, G. (2025). Hyaluronic Acid Hybrid Cooperative Complexes Nearing 10 Years of Use: Update on Safety Assessment Based on Post‐Marketing Surveillance Data. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.70197
Vancouver
Salti G, Tateo A, Cassuto D, Arrigoni F, Godina C, Mazzola F, et al. Hyaluronic Acid Hybrid Cooperative Complexes Nearing 10 Years of Use: Update on Safety Assessment Based on Post‐Marketing Surveillance Data. Journal of Cosmetic Dermatology. 2025. doi:10.1111/jocd.70197
BibTeX
@article{Salti2025,
author = {Salti, Giovanni and Tateo, Antonello and Cassuto, Daniel and Arrigoni, Francesca and Godina, Chiara and Mazzola, Federica and Cigni, Clara and Grimolizzi, Franco and Bellia, Gilberto},
title = {Hyaluronic Acid Hybrid Cooperative Complexes Nearing 10 Years of Use: Update on Safety Assessment Based on Post‐Marketing Surveillance Data},
journal = {Journal of Cosmetic Dermatology},
year = {2025},
doi = {10.1111/jocd.70197}
}
EUVIMED